Skip to main content
. 2021 Sep 24;2021:9959946. doi: 10.1155/2021/9959946

Table 2.

The efficacy was evaluated at the first follow-up (RECIST1.1).

Evaluation n (%)
CR 0 (0)
PR 4 (12.12)
SD 12 (36.36)
PD 17 (51.52)
DCR 16 (48.48)
ORR 4 (12.12)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; ORR, objective response rate.